Prognostic analysis of TURBT combined with epirubicin in the treatment of superficial bladder cancer

Abstract

Objective To investigate the effect of transurethral resection of bladder tumor (TURBT) combined with epirubicin for the serum vascular endothelial growth factor (VEGF) level and survival prognosis in patients with superficial bladder cancer. Methods From June 2011 to June 2016, 100 patients with superficial bladder cancer were selected in our hospital. All patients were randomly divided into mitomycin group and epirubicin group, 50 cases in each group, mitomycin group was treated with 40 mg mitomycin after the operation, epirubicin group was treated with 50 mg epirubicin after the operation. Results VEGF levels of mitomycin group and epirubicin group at 3, 6 months after treatment were significantly lower than those of the before treatment, VEGF levels of epirubicin group were significantly lower than those of mitomycin group at 3, 6 months after treatment, the difference was statistically significant (P 0.05). Cumulative survival rate of epirubicin group was significantly higher than those of mitomycin group, and cumulative recurrence rate of epirubicin group was significantly lower than those of mitomycin group at 1 year, 2 years, 3 years, and the difference was statistically significant (P<0.05). Conclusions TURBT combined epirubicin can effectively reduce postoperative recurrence and improve survival prognosis in patients with bladder cancer, it may be associated with reducing the serum VEGF level in patients, and it has a good safety, it's worth for further clinical promotion. Key words: Urinary Bladder Neoplasms; Cystectomy; Epirubicin; Prognosis